Sign inJoin waitlistJoin the waitlist

TS

Tanya Siddiqi

Medical Director, Lymphoma, City of Hope Orange County · City of Hope National Medical Center

Credentials: · · · ·

History

Lymphoma · City of Hope National Medical Center
Present
Chronic Lymphocytic Leukemia Program · City of Hope National Medical Center
Present
Medical Director of Lymphoma · City of Hope National Medical Center
Present

City of Hope National Medical Center
2009–2010
Beth Israel Deaconess Medical Center
2006–2009
Internal Medicine
Univ of Connecticut Health Center/John Dempsey Hospital
2003–2006
Aga Khan University Medical College Pakistan
1996–2000

Research

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
New England Journal of Medicine · 2017 · 4,914 citations
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
The Lancet · 2020 · Last of 22 authors · 2,058 citations
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
The Lancet Oncology · 2019 · 1,921 citations

Leslie Popplewell
21 papers
Stephen Forman
21 papers
AH
Alex Herrera
18 papers · 1 as a fellow
AD
Alexey Danilov
17 papers
William Wierda
17 papers · 3 as a fellow
Steven Rosen
16 papers
Elizabeth Budde
15 papers
MM
Matthew Mei
13 papers
Thomas Kipps
13 papers
Brian Hill
12 papers
Deborah Stephens
12 papers
Jennifer Brown
12 papers

Grants

Intracerebroventricular (ICV) Administration of CD19-Targeting Chimeric Antigen Receptor (CAR) T Cells for Treatment of Primary Central Nervous System Lymphoma
National Cancer Institute · R01
PI · $3.2M · Beckman Research Institute/City of Hope
2022–2028

Clinical trials

Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial
Principal investigator · Not yet recruiting · Phase 2
City of Hope Medical Center
2027–2028
Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma
Principal investigator · Recruiting · Phase 1
City of Hope Medical Center
2023–2028
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
Principal investigator · Active not recruiting · Phase 2
City of Hope Medical Center
2023–2026
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
Principal investigator · Active not recruiting · Phase 1
City of Hope Medical Center
2014–2026